Searched for
UDENYCA
Intas Pharma completes acquisition of UDENYCA biosimilar for $558 millionIntas Pharma finalized its acquisition of UDENYCA, a biosimilar to Neulasta, from Coherus Life Sciences for $558 million in December 2024. ...- Pharma & healthcare deals see shifting focus on scalable, global models: Grant Thornton BharatIndia's pharma and healthcare sector demonstrates resilient investor interest, marked by a 34% year-on-year increase in deal volumes and a ...
- Biosimilar brand buy to help Intas Pharma take on biggiesIn one of the biggest deals worldwide for a biosimilar brand, Ahmedabad-based Intas agreed to buy Udenyca-the brand name for medication peg...
- Sell Biocon, target Rs 185: Kotak Institutional EquitiesBiocon is a largecap company, operating in pharmaceuticals and health care sector.
Load More